CoreCivic: The Cigar's Been Smoked (Rating: Hold)

CoreCivic has had a remarkable run — up 70% in 120 days and 69% year-to-date — driven by ICE facility activations, political tailwinds, and a transformative $1.5 billion sale of two facilities to the Department of Homeland Security. The stock moved from $15.74 on its 52-week low to $32.27. That kind of move doesn't happen because a stock is "discovered." It happens because the fundamental thesis that kept the stock depressed has been resolved.

The question is no longer whether CoreCivic's assets are valuable. The market just answered that. The question is whether there's still a valuation gap after the market has priced in the facility sale, the leverage reduction, and the immigration policy tailwind. The evidence suggests the cigar has been smoked.

The Earnings Beat — And What It Hides

CoreCivic reported Q2 2026 revenue of $684.9 million, up 27.3% year-over-year. Diluted EPS came in at $0.37, and normalized funds from operations hit $0.64 per share, well above the $0.39 consensus. Residential occupancy rose to 78.4% from 76.8%. Federal customers, primarily ICE and the U.S. Marshals Service, now generate approximately 53% of total revenue.

Those are solid numbers. But they obscure the dominant event of the quarter, which occurred after the books closed.

CoreCivic sold four immigration detention facilities to DHS for $2.2 billion in gross proceeds. The gain on sale — approximately $1.8 billion — will be booked in Q3 2026 and will inflate full-year 2026 diluted EPS to guidance of $15.00–$15.20. That's not a typo. That's what happens when you sell hard assets at multiples far exceeding book value. The California City facility alone sold for $732.6 million on a 2,560-bed operation; Otay Mesa brought $739.2 million for 1,994 beds. That's roughly $307,000 per bed, a price that reflects DHS's desperate need for detention capacity, not a multiple that will repeat.

The meaningful earnings number is adjusted diluted EPS guidance of $1.62–$1.70 for the full year. That strips out the one-time gain and reflects the underlying operating business. At the current price of $32.27 and the midpoint of that range ($1.66), the stock trades at roughly 19.4 times forward adjusted earnings. Not cheap. Not absurd. Fair value for a business with improving occupancy and a dramatically improved balance sheet.

The Balance Sheet: From Trap to Clean

This is where the thesis actually changed. Before the facility sales, CoreCivic carried $2.017 billion in total debt, $108.9 million in cash, and net leverage of 2.9x adjusted EBITDA. Debt-to-equity sat at 93.6%. That's the kind of leverage that keeps a stock depressed — not because the business is failing, but because debt service in a downturn creates real risk.

Post-sale, the picture is fundamentally different. CoreCivic used $1.1 billion of the facility sale proceeds to retire its entire revolving credit facility ($270 million), both term loans ($207.8 million), and the remaining $238.5 million of its 4.75% senior notes due 2027. Total outstanding debt is now approximately $739.1 million.

Let me put that in context. CoreCivic's market cap is $3.19 billion. Its net debt after the repayment is roughly $630 million (after adding back cash). Debt is now one-fifth of market cap instead of two-thirds. The leverage overhang that kept this stock in cigar-butt territory has been lifted.

The remaining net proceeds are designated for general corporate purposes, including additional share repurchases. The board has expanded its buyback authorization to $1.2 billion, with $755.8 million remaining available.

This is the leveraged equity flywheel in reverse — instead of debt amplifying losses, the debt reduction amplifies per-share value. But the market has already bid the stock up 70% in anticipation of exactly this outcome.

The Free Cash Flow Problem

Here's the gate that the headline numbers don't address. CoreCivic's trailing twelve-month free cash flow is $57.3 million, down 66.4% year-over-year. Operating cash flow of $200.2 million sounds healthy, but capital expenditures of $142.8 million have consumed most of it.

This isn't unusual for CoreCivic. The business is capex-intensive — maintaining and activating detention facilities requires continuous investment. But it does create a tension with the dividend. The forward dividend yield is 5.45%, implying annual dividend payments of roughly $174 million on a $3.19 billion market cap. With FCF of $57.3 million over the trailing twelve months, the dividend is not covered by operating cash flow alone.

The company will need either further margin expansion to push FCF higher, the facility sale proceeds to supplement distribution capacity, or both. The updated 2026 guidance shows adjusted EBITDA of $440.5–$445.5 million, which, after interest, taxes, and capex, should generate substantially more FCF than the trailing twelve months. But FCF coverage of the dividend remains a watch item, not a solved one.

Valuation: The Gap Has Narrowed

At 19.4x forward adjusted earnings, CoreCivic trades at a premium to its main peer, GEO Group, which trades at 13.9x trailing earnings and 12.3x EV/EBITDA versus CoreCivic's 11.5x. The PE gap is notable — CoreCivic commands a 43% earnings multiple premium to GEO, despite both companies operating in the same politically sensitive, government-contracted space.

The premium has a rationale. CoreCivic's residential occupancy (78.4%) is improving, its federal revenue mix has shifted toward the more stable ICE contracts, and its post-sale balance sheet is cleaner. But a 43% multiple premium requires execution, not just a better balance sheet. GEO has been consistently beating earnings estimates — its Q2 2026 EPS of $0.37 beat the $0.29 consensus — and carries a similar debt profile ($2.2 billion in total debt).

More relevant to the valuation question: CoreCivic's PE has expanded from the single digits that marked the $15.74 low to roughly 25x on a TTM basis. That multiple expansion — driven by the facility sale, the buyback program, and the political narrative — has done most of the work. Further multiple expansion would require either the Prairie facility (1,600 beds, $75 million in annual revenue, expected by Q2 2027) to come online ahead of schedule, or additional ICE facility purchases to materialize. Both are possible. Neither is priced in at this level.

What's Next — And What Could Go Wrong

The near-term catalysts are clear. The Prairie facility in Leavenworth, Kansas — idle since 2010 — has a new five-year management contract with ICE. Full activation by Q2 2027 would add roughly $75 million in annual revenue. CoreCivic is also in preliminary discussions with ICE to sell additional detention centers. The company owns nine facilities contracted solely with ICE and 56 total correctional and detention facilities.

The risks are equally concrete. Government contracts remain subject to appropriations — ICE can terminate for non-appropriation of funds or for convenience. The political tailwind that drove this stock higher is inherently dependent on budget cycles and policy continuity. If ICE funding stalls, occupancy at federal facilities drops, and the revenue growth driving the current earnings trajectory unwinds. There's also the regulatory overhang: California, Colorado, New Jersey, and Washington have passed laws empowering local inspections of private prisons, which is precisely why DHS bought four CoreCivic facilities in the first place. The remaining portfolio faces similar scrutiny.

The Rating

CoreCivic was a textbook cigar-butt play. Hard-to-replace physical assets, resilient government contracts, manageable — if elevated — debt, and a market that had over-discounted political headwinds. The $2.2 billion facility sale validated that thesis. The debt reduction from $2.0 billion to $739 million confirmed that the balance sheet was always strong enough to execute.

But the 70% move in 120 days has closed the valuation gap. At 19.4x forward adjusted earnings, the stock is priced for continued occupancy growth, margin expansion, and additional facility sales. It's not expensive by historical standards, but it's no longer the mispriced asset that made this position compelling at $16.

Rating: Hold. The thesis has been realized. New positions at $32 are paying fair value for a business whose political tailwinds are real but temporary and whose dividend coverage remains tight. Existing holders have already captured the upside from the leverage reduction and asset re-rating. The gate that determines whether this becomes a Buy again is whether recurring adjusted earnings can grow above $2.00 per share — requiring the Prairie facility, additional activations, and sustained federal funding — while maintaining free cash flow sufficient to cover the dividend without relying on capital market transactions. If that happens, the stock re-earns a Buy. Until then, the work is done.

This is not a momentum trade. It's a position whose role has shifted from opportunistic value to a holding that needs operational execution to justify further commitment. For a retirement portfolio focused on income and compounding, the 5.45% dividend yield is attractive in isolation — but the FCF coverage question means this yield is not yet the durable, self-sustaining kind that serves as a retirement anchor.